Sponsors

Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine. Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or even save lives.

As the philanthropic arm of Anthem, Inc., the Anthem Foundation promotes the organization's commitment to enhance the health and well-being of individuals and families in the communities it serves. They believe that giving back is not only a privilege, it's a responsibility. 

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing novel combination medicines for people with cancer. Arcus is working in partnership with industry, patients and physicians around the world to investigate potential new cancer immunotherapy combinations in areas of high unmet need, including lung, colorectal, prostate, gastrointestinal and other cancers.

Bayer is a global life sciences leader in healthcare and nutrition. Building on a 150-year legacy in healthcare, Bayer is committed to improving patient lives by developing innovative therapies and delivering first-in-class educational and support programs to meet their needs.

Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, Boston Scientific advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com.

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life by providing the highest-quality biopharmaceutical products. They are focused on both finding innovative medicines to combat serious diseases and on getting them to patients faster and more efficiently.

Launched in 2002 for patients with cancer, survivors and their caregivers, CURE® Media Group’s flagship magazine and online resource curetoday.com provide access to leading resources and information that serve as a guide to every stage of the cancer experience. In 2014, MJH Life Sciences™ acquired Cure Media Group, and since then our award-winning editorial and creative teams deliver Cancer Updates, Research, and Education to connect the cancer community and empower individual journeys.

Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, IV iron therapy, metastatic melanoma, tenosynovial giant cell tumors and metastatic breast cancer. Visit www.dsi.com.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology. Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. To learn more, please visit us at www.eisai.com/US.

Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis. We combine advancements in technology with an evolving understanding of terminal diseases to develop best-in-class medicines with the potential to reverse the most severe health conditions. We are a highly qualified, innovative and focused team that has come together to live up to our name and bold mission: to help patients feel better and live longer.

Exact Sciences is committed to playing a role in the eradication of colorectal cancer. As part of this mission, we are to introduce Cologuard, intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool.

Genentech BioOncology is an industry leader in researching the molecular basis of cancer with a long-standing commitment to fundamentally transforming the way cancer is treated. Genentech believes that studying the biological pathways involved in cancer development, progression and metastasis holds the key to identifying promising molecular targets. Genentech BioOncology is focused on both the basic biology of cancer and its application to therapeutics in oncology.

Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. 

Hood Container Corporation is a family-owned, Mill to Market company specializing in containerboard and kraft paper, corrugated boxes, high graphic displays, and contract packaging. Over the last decade, Hood Container Corporation has grown to become one of the top ten Paper and Packaging Companies in the United States.

Independence Blue Cross (IBX) is the leading health insurance organization in southeastern Pennsylvania. With our affiliates, we serve more than 8 million people nationwide, including 2.5 million in the region. For 80 years, IBC has been enhancing the health and well-being of the people and communities they serve by delivering innovative and competitively priced health care products and services; pioneering new ways to reward doctors, hospitals, and other health care professionals for coordinated, quality care; and supporting programs and events that promote wellness.

Intuitive is a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. Intuitive brings more than two decades of leadership in robotic-assisted surgical technology and solutions to its offerings, and develops, manufactures, and markets the da Vinci surgical system.

LetsGetChecked is a leading health insights company that allows consumers direct access to a wide range of testing options and clinical support from home. Founded in 2015, the company empowers people to take an active role in their health to live longer, happier lives. By combining health data and diagnostic results, LetsGetChecked provides rich health insights to enable better healthcare decision-making. LetsGetChecked tests cover general health, men's health, women's health, and sexual health, and are available nationwide in the US and most EU countries. LetsGetChecked has corporate offices located in New York City and Dublin. For more information, visit www.letsgetchecked.com.

Medtronic is a global healthcare solutions company that is committed to improving lives through our medical technologies, services, and solutions. 

Merck aspires to make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future. 

Signatera is a custom-built, circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer. Signatera's tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in detecting low levels of ctDNA and identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Learn more at natera.com/signatera.

NeoGenomics is a premier cancer diagnostic, pharma services, and information services company serving oncologists, pathologists, pharmaceutical companies, and academic centers in their pursuit of providing better futures for people living with cancer. Learn more at www.neogenomics.com. 

Olympus is a global technology leader, crafting innovative optical and digital solutions in medical technologies; life sciences; industrial solutions; and cameras and audio products. Throughout our nearly 100-year history, Olympus has focused on being true to society and making people’s lives healthier, safer and more fulfilling every day. Visit www.olympusamerica.com.

Pfizer is grounded in our commitment to fund programs that provide public benefit, advance medical care and improve patient outcomes. Our belief is that all people deserve to live healthy lives. This drives our desire to provide access to medicines that are safe, effective, and affordable.

Salix is committed to being the leading U.S. specialty pharmaceutical company licensing, developing and marketing innovative products to healthcare professionals to prevent or treat gastrointestinal disorders in patients while providing rewarding opportunities for our employees and creating exceptional value for our stockholders.

The Sampson Foundation strives to create healthy communities by promoting access, awareness, research and education on healthy food choices and integrative medicine.

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com.

StopColonCancerNow is a network of expertly trained gastroenterologists who combat the second deadliest form of cancer, colon cancer, through community education and colonoscopy – the gold standard of screenings. StopColonCancerNow.com is your resource for colon cancer and colonoscopy, the best way to prevent and detect this disease.

Taiho Oncology, Inc. works urgently to discover and develop innovative cancer treatments. As cancer evolves, we evolve with it—bringing novel technology to cornerstone chemotherapies, while at the same time optimizing new targeted agents. Advanced technology, dedicated investigators, and incomparable facilities—these vast resources empower us to redefine the way the world treats cancer.